+

CN115867581A - Chimeric antigen receptors containing protective peptides and uses thereof - Google Patents

Chimeric antigen receptors containing protective peptides and uses thereof Download PDF

Info

Publication number
CN115867581A
CN115867581A CN202180019196.7A CN202180019196A CN115867581A CN 115867581 A CN115867581 A CN 115867581A CN 202180019196 A CN202180019196 A CN 202180019196A CN 115867581 A CN115867581 A CN 115867581A
Authority
CN
China
Prior art keywords
chimeric antigen
discloses
chain variable
variable region
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019196.7A
Other languages
Chinese (zh)
Inventor
丁艳萍
鲁薪安
何霆
齐菲菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Yimiao Shenzhou Pharmaceutical Technology Co ltd
Original Assignee
Beijing Yimiao Shenzhou Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Yimiao Shenzhou Pharmaceutical Technology Co ltd filed Critical Beijing Yimiao Shenzhou Pharmaceutical Technology Co ltd
Publication of CN115867581A publication Critical patent/CN115867581A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种分离的抗原结合结构域，其包括能够结合抗原的单链可变区片段，其包括轻链可变区和重链可变区；和一个或多个保护肽。本发明还公开了分离的嵌合抗原受体的铰链区、穿膜区、共刺激信号结构域以及胞内信号转导结构域。本发明还公开了包含所述抗原结合结构域的分离的嵌合抗原受体、编码抗原结合结构域或嵌合抗原受体的核酸分子、载体、宿主细胞、组合物和制备方法，所述宿主细胞或组合物用于制备治疗癌症或病毒感染等疾病的药物。The present invention discloses an isolated antigen binding domain comprising a single chain variable region fragment capable of binding antigen, comprising a light chain variable region and a heavy chain variable region; and one or more protective peptides. The invention also discloses the hinge region, transmembrane region, co-stimulatory signal domain and intracellular signal transduction domain of the isolated chimeric antigen receptor. The invention also discloses an isolated chimeric antigen receptor comprising the antigen binding domain, a nucleic acid molecule encoding an antigen binding domain or chimeric antigen receptor, a vector, a host cell, a composition and a preparation method, the host The cells or compositions are used to prepare medicines for treating diseases such as cancer or viral infection.

Description

PCT国内申请，说明书已公开。PCT domestic application, specification has been published.

Claims (31)

PCT国内申请，权利要求书已公开。PCT domestic application, the claims have been published.
CN202180019196.7A 2020-03-25 2021-03-24 Chimeric antigen receptors containing protective peptides and uses thereof Pending CN115867581A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020102208423 2020-03-25
CN202010220842 2020-03-25
PCT/CN2021/082682 WO2021190550A1 (en) 2020-03-25 2021-03-24 Chimeric antigen receptor containing protective peptide, and use thereof

Publications (1)

Publication Number Publication Date
CN115867581A true CN115867581A (en) 2023-03-28

Family

ID=77890654

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180019196.7A Pending CN115867581A (en) 2020-03-25 2021-03-24 Chimeric antigen receptors containing protective peptides and uses thereof
CN202411370108.XA Pending CN119264269A (en) 2020-03-25 2021-03-24 Chimeric antigen receptors binding to CD19 and uses thereof
CN202180019189.7A Active CN115335407B (en) 2020-03-25 2021-03-24 Chimeric antigen receptor binding to CD19 and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411370108.XA Pending CN119264269A (en) 2020-03-25 2021-03-24 Chimeric antigen receptors binding to CD19 and uses thereof
CN202180019189.7A Active CN115335407B (en) 2020-03-25 2021-03-24 Chimeric antigen receptor binding to CD19 and uses thereof

Country Status (2)

Country Link
CN (3) CN115867581A (en)
WO (2) WO2021190551A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160124A1 (en) * 2020-02-13 2021-08-19 北京艺妙神州医药科技有限公司 Optimization of chimeric antigen receptor
CN117143248A (en) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 Bispecific chimeric antigen receptor targeting BCMA-CD19 and application thereof
CN116836282B (en) * 2023-02-13 2024-03-29 北京艺妙神州医药科技有限公司 Antibodies, chimeric antigen receptors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016283A2 (en) * 2003-08-15 2005-02-24 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
CN101270163A (en) * 2008-04-22 2008-09-24 中山大学 A kind of single-chain fragment antibody-polypeptide fusion protein and its application
CN103910799A (en) * 2014-03-06 2014-07-09 中国人民解放军第四军医大学 A fusion protein based on anti-EGFR single-chain antibody and arginine nonamer and its application
CN105980402A (en) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 Tagged chimeric effector molecules and receptors thereof
CN107075482A (en) * 2014-04-07 2017-08-18 诺华股份有限公司 Using the Anti-CD19 Chimeric Antigen Receptor to Treat Cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502598A (en) * 2001-06-07 2005-01-27 メドベット・サイエンス・プロプライエタリー・リミテッド Methods of treatment by regulating cytokine-mediated cellular activity and substances useful therefor
CN111848801B (en) * 2016-09-06 2022-10-11 上海吉倍生物技术有限公司 anti-CD 19 antibody and preparation method and application thereof
CN110352197B (en) * 2016-12-09 2024-02-02 Uab研究基金会 Chimeric chlorotoxin receptors
CA3096500A1 (en) * 2018-04-13 2019-10-17 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
CN110819596B (en) * 2018-11-29 2023-10-27 浙江煦顼技术有限公司 Modified cells with enhanced migration ability
CN110903401A (en) * 2019-11-20 2020-03-24 浙江大学 Second-generation chimeric antigen receptor targeting CD19, and expression vector and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016283A2 (en) * 2003-08-15 2005-02-24 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
CN101270163A (en) * 2008-04-22 2008-09-24 中山大学 A kind of single-chain fragment antibody-polypeptide fusion protein and its application
CN105980402A (en) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 Tagged chimeric effector molecules and receptors thereof
CN103910799A (en) * 2014-03-06 2014-07-09 中国人民解放军第四军医大学 A fusion protein based on anti-EGFR single-chain antibody and arginine nonamer and its application
CN107075482A (en) * 2014-04-07 2017-08-18 诺华股份有限公司 Using the Anti-CD19 Chimeric Antigen Receptor to Treat Cancer

Also Published As

Publication number Publication date
WO2021190551A1 (en) 2021-09-30
CN115335407A (en) 2022-11-11
CN115335407B (en) 2024-08-27
WO2021190550A1 (en) 2021-09-30
CN119264269A (en) 2025-01-07

Similar Documents

Publication Publication Date Title
CN115867581A (en) Chimeric antigen receptors containing protective peptides and uses thereof
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
JP2018029595A5 (en)
JP2018172439A5 (en)
EP4282978A3 (en) A universal platform for car therapy targeting a novel antigenic signature of cancer
EP4032544A3 (en) Novel t cell receptors and immune therapy using the same
JP2018512856A5 (en)
JP2017537627A5 (en)
JP2018524001A5 (en)
CA2918780A1 (en) Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1
PH12019502847A1 (en) Novel t cell receptors and immune therapy using the same
CY1113089T1 (en) Human Monoclonal Antibodies to Specific Protective Membrane Antigen (PSMA)
BRPI0712716A2 (en) fusion protein, composition, nucleic acid construction, vector, transformed cell, isolated preparation of bacterially expressed inclusion bodies, process for producing a fusion protein, and methods for selectively killing a tumor cell and for treating a tumor cell expressing mesothelin on its surface
JP2014515602A5 (en)
JP2019535292A5 (en)
JPWO2020069028A5 (en)
CN108047332A (en) Using CD19 as the specific antibody of target spot, CAR-NK cells and its preparation and application
JP2019513394A5 (en)
JP2025060882A5 (en)
JP2019517790A5 (en)
CN103965362B (en) A kind of chimeric chemokine receptor for making T cell tend to tumor locus
Schafer et al. KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys
CN110144328A (en) A kind of antitumor T cell of targeting and its preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: 100195 No.316, 3rd floor, building 1, block B, 80 xingshikou Road, Haidian District, Beijing

Applicant after: Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd.

Address before: 100195 No.316, 3rd floor, building 1, block B, 80 xingshikou Road, Haidian District, Beijing

Applicant before: Beijing Yimiao Shenzhou Pharmaceutical Technology Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载